EGFR and neoplasm: In addition, the transformation of tumor tissue types, epithelial mesenchymal change, epigenetic changes, and abnormal microenvironment of tumor cells may cause resistance to EGFR‐TKIs; the mechanisms for approximately 18%–20% of cases with acquired resistance remain unknown.